APLM (Apollomics) Ending Cash Position: $3.28 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APLM Apollomics Inc APLM
31 GF Score
Price $18.86
! 4 Warning Signs
View Full Analysis

What is Apollomics Ending Cash Position?

Apollomics APLM +1.84% 31 Ending Cash Position is $3.28 Mil as of Dec. 2025. GuruFocus rates APLM with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Apollomics's Ending Cash Position for the quarter that ended in Dec. 2025 was $3.28 Mil.

Apollomics's quarterly Ending Cash Position declined from Dec. 2024 ($9.77 Mil) to Jun. 2025 ($2.09 Mil) but then increased from Jun. 2025 ($2.09 Mil) to Dec. 2025 ($3.28 Mil).

Apollomics's annual Ending Cash Position declined from Dec. 2023 ($32.06 Mil) to Dec. 2024 ($9.77 Mil) and declined from Dec. 2024 ($9.77 Mil) to Dec. 2025 ($3.28 Mil).

Apollomics Ending Cash Position Related Terms

Apollomics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Apollomics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics Ending Cash Position Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 46.74 32.68 32.06 9.77 3.28

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 32.06 25.93 9.77 2.09 3.28
APLM
31GF Score
Apollomics Inc APLM
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Apollomics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=9.766+-6.49
=3.28

Apollomics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2.094+1.182
=3.28

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $3.28 Mil mean?
Apollomics (APLM) has a Ending Cash Position of $3.28 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Apollomics and its competitors.
Is Apollomics' Ending Cash Position too high?
Apollomics' current Ending Cash Position is $3.28 Mil. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Ending Cash Position compare to HYPD and MGX?
Apollomics' Ending Cash Position of $3.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Apollomics and its competitors. Apollomics's current Ending Cash Position is $3.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLM) has a current Ending Cash Position of $3.28 Mil. The current Ending Cash Position is $3.28 Mil. Apollomics' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Apollomics (APLM), the current Ending Cash Position is $3.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLMW:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score

Get the complete analysis for APLM

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.86
Price